JANX
Janux Therapeutics Inc
16.90$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +26.8% | +140.5% | +39.4% | -1.7% | +48.8% | -23.3% | +56.9% | -28.0% | -48.4% | +138.1% | -2.2% | -49.1% | +610.6% | -95.1% | -2,039.0% | – | – | – | -21.2% | -52.6% | +175.0% | – | |
| – | +22.6% | +23.9% | +18.1% | +95.4% | +146.1% | +77.5% | +32.9% | -8.8% | +38.3% | -2.5% | +12.4% | +2.8% | -5.9% | -96.6% | +6.2% | +0.2% | -4.9% | +369.2% | +776.4% | +20.4% | +16.4% | -98.3% | +1,684.4% | -94.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -4.3% | -62.7% | +1,065.4% | -123.1% | – | – | – | – | -111.2% | – | +214.6% | – | |
| – | +22.6% | +23.9% | +18.1% | +95.4% | +146.1% | +77.5% | +32.9% | -8.8% | +38.3% | -2.5% | +12.4% | +2.8% | -5.9% | -20.3% | +2.9% | +14.9% | +5.9% | +24.9% | +11.8% | +20.4% | +38.4% | -0.1% | -8.9% | -15.0% | +15.6% | – | |
| – | +56.3% | -2.5% | +58.8% | +10.3% | +170.2% | +83.1% | +7.7% | +25.7% | +12.0% | +10.1% | -6.9% | +13.9% | +6.5% | -6.4% | -1.3% | +15.5% | +6.5% | +125.9% | -53.5% | +19.8% | +6.2% | +1.6% | +2.2% | +2.6% | -1.5% | – | |
| – | +33.9% | +13.6% | +31.8% | -55.3% | +170.2% | +83.1% | +7.7% | +25.7% | +12.0% | +10.1% | -6.9% | +13.9% | +6.5% | +159.1% | +1.3% | +15.6% | +6.4% | +52.6% | -75.8% | +19.8% | +62.0% | +180.7% | -7.6% | -9.3% | +12.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +12.4% | -100.0% | – | – | – | +197.8% | -46.0% | +78.4% | +182.6% | +255.5% | +66.0% | +48.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +197.8% | -154.0% | – | – | – | – | – | – | -243.3% | – | -48.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.